Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 9, 2016, Pages 1072-1078

  Skaper, Stephen D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Blood brain barrier; Mast cells; Microglia; Neuroinflammation; Neuropathic pain; Palmitoylethanolamide

Indexed keywords

ABC TRANSPORTER SUBFAMILY B; ACID HYDROLASE; ADENOSINE TRIPHOSPHATE; CALPAIN 2; CD34 ANTIGEN; CHYMASE; CYTOKINE; GAMMA INTERFERON; HISTAMINE; HYDROLASE; IMMUNOGLOBULIN E; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LEUKOTRIENE C4; N ACYLETHANOLAMINE; NERVE GROWTH FACTOR; NEUROPEPTIDE; NEUTRAL PROTEINASE; NITRIC OXIDE; PEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPASE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; RANTES; SEROTONIN; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE ACTIVATING FACTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRYPASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ASTROCYTE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; CELLULAR HOMEOSTASIS; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; ENDONEURIUM; GLIA; HUMAN; INNATE IMMUNITY; MAST CELL; MAST CELL DEGRANULATION; MEMBRANE PERMEABILITY; METABOLITE; MICROVASCULATURE; NERVE EDEMA; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NERVE; PHAGOCYTOSIS; REVIEW; SENSORY NERVE FIBRE; ANIMAL; IMMUNOLOGY; NEURALGIA;

ANIMALS; BLOOD-BRAIN BARRIER; CHRONIC PAIN; HUMANS; MAST CELLS; NEURALGIA; NEUROGLIA;

EID: 85011756092     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160829105533     Document Type: Review

References (114)

1. Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 2004; 16: 1-13.
2. Kim JH, Kim JH, Park JA, et al. Blood-neural barrier: intercellular communication at glio-vascular interface. J Biochem Mol Biol 2006; 39: 339-45.
3. Allt G, Lawrenson JG. The blood-nerve barrier: enzymes, transporters and receptors--a comparison with the blood-brain barrier. Brain Res Bull 2000; 52: 1-12.
4. Marieb EN, Hoehn K. Human Anatomy & Physiology, 7th ed. London: Pearson, 2007.
5. Kanda, T. Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. Neurol Neurosurg Psychiatry 2013; 84: 208-12.
6. Olsson Y. Microenvironment and the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol 1990; 5: 265-311.
7. Mizisin AP, Kalichman MW, Myers RR, Powell HC. Role of the blood-nerve barrier in experimental nerve edema. Toxicol Pathol 1990; 18: 170-85.
8. Hahn AF, Feasby TE, Gilbert JJ. Blood-nerve barrier studies in experimental allergic neuritis. Acta Neuropathol 1985; 68: 101-9.
9. Rechthand E, Smith QR, Latker CH, Rapoport SI. Altered blood-nerve barrier permeability to small molecules in experimental diabetes mellitus. J Neuropathol Exp Neurol 1987; 46: 302-314.
10. Poduslo JF, Curran GL. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci USA 1992; 89: 2218-22.
11. Powell HC, Myers RR, Costello ML, Lampert PW. Endoneurial fluid pressure in wallerian degeneration. Ann Neurol 1979; 5: 550-7.
12. Lundborg G. Ischemic nerve injury. Experimental studies on intraneural microvascular pathophysiology and nerve function in a limb subjected to temporary circulatory arrest. Scand J Plast Reconstr Surg Suppl 1970; 6: 3-113.
13. Lundborg G. Structure and function of the intraneural microvessels as related to trauma, edema formation, and nerve function. J Bone Joint Surg Am 1975; 57: 938-48.
14. Hirakawa H, Okajima S, Nagaoka T, Takamatsu T, Oyamada M. Loss and recovery of the blood-nerve barrier in the rat sciatic nerve after crush injury are associated with expression of intercellular junctional proteins. Exp Cell Res 2003; 284: 196-210.
15. Enerbaeck L, Olsson Y, Sourander P. Mast cells in normal and sectioned peripheral nerve. Z Zellforsch Mikrosk Anat 1965; 66: 596-608.
16. Olsson Y. The effect of the histamine liberator, Compound 48-80 on mast cells in normal peripheral nerves. Acta Pathol Microbiol Scand 1966; 68: 563-74.
17. Olsson Y. Studies on vascular permeability in peripheral nerves. 1. Distribution of circulating fluorescent serum albumin in normal, crushed and sectioned rat sciatic nerve. Acta Neuropathol 1966; 7: 1-15.
18. Olsson Y. Topographical differences in the vascular permeability of the peripheral nervous system. Acta Neuropathol 1968; 10: 26-33.
19. Powell HC, Myers RR, Costello ML. Increased endoneurial fluid pressure following injection of histamine and compound 48/80 into rat peripheral nerves. Lab Invest 1980; 43: 564-72.
20. Harvey GK, Toyka KV, Hartung HP. Effects of mast cell degranulation on blood-nerve barrier permeability and nerve conduction in vivo. J Neurol Sci 1994; 125: 102-9.
21. Ehrlich P. Beiträge zur Theorie und Praxis der histologischen Färbung (Contribution to the theory and practice of histological dyes). Leipzig Univ 1994; OCLC 63372150.
22. Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci USA 2005; 102: 11408-13.
23. Marieb EN, Hoehn K. Human Anatomy and Physiology, 7th ed.; San Francisco: Pearson Benjamin Cummings, 1994.
24. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003; 111(Suppl 2): S486-94.
25. Gilfillan AM, Austin SJ, Metcalfe DD. Mast cell biology: introduction and overview. Adv Exp Med Biol 2011; 716: 2-12.
26. Lambracht-Hall M, Dimitriadou V, Theoharides TC. Migration of mast cells in the developing rat brain. Dev Brain Res 1990; 56: 151-9.
27. Moon TC, St Laurent CD, Morris KE, et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010; 3: 111-28.
28. Gauchat JF, Henchoz S, Mazzei G, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365: 340-3.
29. Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986; 78: 1701-6.
30. Perry VH, Andersson PB, Gordon G. Macrophages and inflammation in the central nervous system. Trends Neurosci 1993; 16: 268-73.
31. Harvey GK, Toyka KV, Hartung HP. Effects of mast cell degranulation on blood-nerve barrier permeability and nerve conduction in vivo. J Neurol Sci 1994; 125: 102-9.
32. Kalichman MW, Powell HC, Calcutt NA, Mizisin AP. Mast cell degranulation and blood-nerve barrier permeability in rat sciatic nerve after 7 days of hyperglycemia. Am J Physiol 1995; 268(2 Pt 2): H740-8.
33. Endres M, Engelhardt B, Koistinaho J, et al. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis 2008; 25: 268-78.
34. Jordán J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008; 14: 3549-64.
35. González-Scarano F, Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999; 22: 219-40.
36. Chew LJ, Takanohashi A, Bell M. Microglia and inflammation: impact on developmental brain injuries. Ment Retard Dev Disabil Res Rev 2006; 12: 105-12.
37. Bona E, Andersson AL, Blomgren K, et al. Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res 1999; 45: 500-9.
38. Cowell RM, Xu H, Galasso JM, Silverstein FS. Hypoxic-ischemic injury induces macrophage inflammatory protein-1alpha expression in immature rat brain. Stroke 2002; 33: 795-801.
39. Ribatti D. The crucial role of mast cells in blood-brain barrier alterations. Exp Cell Res 2015; 338: 119-25.
40. Silver R, Silverman AJ, Vitković L, Lederhendler II. Mast cells in the brain: evidence and functional significance. Trends Neurosci 1996; 19: 25-31.
41. Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman AJ. Brain mast cell relationship to neurovasculature during development. Brain Res 2007; 1171: 18-29.
42. Silverman AJ, Sutherland AK, Wilhelm M, Silver R. Mast cells migrate from blood to brain. J Neurosci 2000; 20: 401-8.
43. Lindsberg PJ, Strbian D, Karjalainen-Lindsberg ML. Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage. J Cereb Blood Flow Metab 2010; 30: 689-702.
44. Biran V, Cochois V, Karroubi A, Arrang JM, Charriaut-Marlangue C, Héron A. Stroke induces histamine accumulation and mast cell degranulation in the neonatal rat brain. Brain Pathol 2008; 18: 1-9.
45. Hu W, Xu L, Pan J, Zheng X, Chen Z. Effect of cerebral ischemia on brain mast cells in rats. Brain Res 2004; 1019: 275-80.
46. Jin Y, Silverman AJ, Vannucci SJ. Mast cells are early responders after hypoxia-ischemia in immature rat brain. Stroke 2009; 40: 3107-12.
47. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ. Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006; 26: 605-12.
48. Mattila OS, Strbian D, Saksi J, et al. Cerebral mast cells mediate blood-brain barrier disruption in acute experimental ischemic stroke through perivascular gelatinase activation. Stroke 2011; 42: 3600-5.
49. Jin Y, Silverman AJ, Vannucci SJ. Mast cell stabilization limits hypoxic-ischemic brain damage in the immature rat. Dev Neurosci 2007; 29: 373-84.
50. Strbian D, Tatlisumak T, Ramadan UA, Lindsberg PJ. Mast cell blocking reduces brain edema and hematoma volume and improves outcome after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 27: 795-802.
51. McKittrick CM, Lawrence CE, Carswell HV. Mast cells promote blood brain barrier breakdown and neutrophil infiltration in a mouse model of focal cerebral ischemia. J Cereb Blood Flow Metab 2015; 35: 638-47.
52. Terrando N, Brzezinski M, Degos V, et al. Perioperative cognitive decline in the aging population. Mayo Clin Proc 2011; 86: 885-93.
53. Riedel B, Browne K, Silbert B. Cerebral protection: inflammation, endothelial dysfunction, and postoperative cognitive dysfunction. Curr Opin Anaesthesiol 2014; 27: 89-97.
54. Eckenhoff RG, Laudansky KF. Anesthesia, surgery, illness and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2013; 47: 162-6.
55. Zhang S, Dong H, Zhang X, Li N, Sun J, Qian Y. Cerebral mast cells contribute to postoperative cognitive dysfunction by promoting blood brain barrier disruption. Behav Brain Res 2016; 298: 158-66.
56. Peferoen LA, Vogel DY, Ummenthum K, et al. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J Neuropathol Exp Neurol 2015; 74: 48-63.
57. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 2014; 8: 112.
58. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron 2014; 81: 1009-23.
59. Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci 2014; 15: 300-12.
60. Carson MJ. Microglia as liaisons between the immune and central nervous systems. Functional implications for multiple sclerosis. Glia 2002; 40: 218-31.
61. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 2010; 126: 56-68.
62. Dong H, Zhang X, Wang Y, Zhou X, Qian Y, Zhang S. Suppression of brain mast cells degranulation inhibits microglial activation and central nervous system inflammation. Mol Neurobiol 2016; [Epub ahead of print].
63. Pietrzak A, Wierzbicki M, Wiktorska M, Brzezińska-Błaszczyk E. Surface TLR2 and TLR4 expression on mature rat mast cells can be affected by some bacterial components and proinflammatory cytokines. Mediators Inflamm 2011; 2011: 427473.
64. Gasque P, Singhrao SK, Neal JW, Götze O, Morgan BP. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997; 150: 31-41.
65. Kim DY, Hong GU, Ro JY. Signal pathways in astrocytes activated by cross-talk between of astrocytes and mast cells through CD40-CD40L. J Neuroinflammation 2011; 8: 25.
66. Wang M, Wang X, Zhao L, et al. Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina. J Neurosci 2014; 34: 3793-806.
67. Skaper SD, Giusti P, Facci, L. Microglia and mast cells: two tracks on the road to neuroinflammation. FASEB J 2012; 26: 3103-17.
68. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140: 871-82.
69. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 2013; 14: 877-82.
70. Mate I, Madrid JA, De la Fuente M. Chronobiology of the neuroimmunoendocrine system and aging. Curr Pharm Des 2014; 20: 4642-55.
71. Nguyen M, Pace AJ, Koller BH. Age-induced reprogramming of mast cell degranulation. J Immunol 2005; 175: 5701-7.
72. Gunin AG, Kornilova NK, Vasilieva OV, Petrov VV. Age-related changes in proliferation, the numbers of mast cells, eosinophils, and cd45-positive cells in human dermis. J Gerontol A Biol Sci Med Sci 2011; 66: 385-92.
73. Tsuboi I, Harada T, Hirabayashi Y, Kanno J, Inoue T, Aizawa S. Age-related decline of mast cell regeneration in senescence-accelerated mice (SAMP1) after chemical myeloablation due to senescent stromal cell impairment. Exp Biol Med 2012; 237: 1289-97.
74. Norden DM, Godbout JP. Review: microglia of the aged brain: primed to be activated and resistant to regulation. Neuropathol Appl Neurobiol 2013; 39: 19-34.
75. Eggen BJ, Raj D, Hanisch UK, Boddeke HW. Microglial phenotype and adaptation. J Neuroimmune Pharmacol 2013; 8: 807-23.
76. Hains LE, Loram LC, Weiseler JL, et al. Pain intensity and duration can be enhanced by prior challenge: initial evidence suggestive of a role of microglial priming. J Pain 2010; 11: 1004-14.
77. Kim DH, Do MS. BAFF knockout improves systemic inflammation via regulating adipose tissue distribution in high-fat diet-induced obesity. Exp Mol Med 2015; 47: e129.
78. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014; 13: 465-76.
79. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15: e493-503.
80. Morris MC, Gilliam EA, Li L. Innate immune programing by endotoxin and its pathological consequences. Front Immunol 2015; 5: 680.
81. Rosenberg GA. Neurological diseases in relation to the blood–brain barrier. J Cereb Blood Flow Metab 2012; 32: 1139-51.
82. DosSantos MF, Holanda-Afonso RC, Lima RL, DaSilva AF, Moura-Neto V. The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci 2014; 8: 302.
83. Brooks TA, Hawkins BT, Huber JD, Egleton RD, Davis TP. Chronic inflammatory pain leads to increased blood-brain barrier permeability and tight junction protein alterations. Am J Physiol Heart Circ Physiol 2005; 289: H738-43.
84. Rapp JH, Pan XM, Neumann M, Hong M, Hollenbeck K, Liu J. Microemboli composed of cholesterol crystals disrupt the blood-brain barrier and reduce cognition. Stroke 2008; 39: 2354-61.
85. Chan-Ling T, Hughes S, Baxter L, et al. Inflammation and breakdown of the blood-retinal barrier during "physiological aging" in the rat retina: a model for CNS aging. Microcirculation 2007; 14: 63-76.
86. Pelisch N, Hosomi N, Mori H, Masaki T, Nishiyama A. RAS inhibition attenuates cognitive impairment by reducing blood-brain barrier permeability in hypertensive subjects. Curr Hypertens Rev 2013; 9: 93-8.
87. O'Callaghan JP, Miller DB. Spinal glia and chronic pain. Metabolism 2010; 59(Suppl 1): S21-6.
88. Tore F, Tuncel N. Mast cells: target and source of neuropeptides. Curr Pharm Des 2009; 15: 3433-45.
89. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007; 105: 838-47.
90. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008; 60: 297-307.
91. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol 2013; 13: 59-66.
92. Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 2013; 166: 166-72.
93. Skaper SD, Facci L. Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3312-25.
94. Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci 2014; 17: 164-74.
95. Genovese T, Esposito E, Mazzon E, et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008; 326: 12-23.
96. Esposito E, Paterniti I, Mazzon E, et al. Effects of palmitoylethanolamide on release of mast cell peptidases and DISCLAIMER: The above article has been published in Epub (aheaEditorial Department reserves the right to make minor modifications fo neurotrophic factors after spinal cord injury. Brain Behav Immun 2011; 25: 1099-112.
97. Ahmad A, Crupi R, Impellizzeri D, et al. Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice. Brain Behav Immun 2012; 26: 1310-21.
98. Esposito E, Impellizzeri D, Mazzon E, Paterniti I, Cuzzocrea S. Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease. PLoS One 2012; 2012: 7.
99. Ahmad A, Genovese T, Impellizzeri D, et al. Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats. Brain Res 2012; 1477: 45-58.
100. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors. Pain 2008; 139: 541-50.
101. Di Cesare Mannelli L, D'Agostino G, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm 2013; 2013: 328797.
102. Mazzari S, Canella R, Petrelli L, Marcolongo G, Leon L. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by downmodulating mast cell activation. Eur J Pharmacol 1996; 300: 227-36.
103. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-81.
104. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189-99.
105. Costa B, Conti S, Giagnoni G, Colleoni M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 2002; 137: 413-20.
106. D'Agostino G, La Rana G, Russo R, et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 2007; 322: 1137-43.
107. D'Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol 2009; 613: 54-9.
108. De Filippis D, Luongo L, Cipriano M, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain 2011; 10: 3.
109. Skaper SD, Facci L, Fusco M, et al. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 2014; 22: 79-94.
110. Fidaleo M, Fanelli F, Ceru MP, Moreno S. Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands. Curr Med Chem 2014; 21: 2803-21.
111. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005; 67: 15-9.
112. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M. Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 2013; 168: 1430-44.
113. Abdulla A, Adams N, Bone M, et al. British Geriatric Society. Guidance on the management of pain in older people. Age Ageing 2013; 42 Suppl 1: i1-57.
114. Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE. Endocannabinoids modulate human blood-brain barrier permeability in vitro. Br J Pharmacol 2015; 172: 3015-27. of print) on the basis of the materials provided by the author. The further improvement of the manuscript. 573801